Global biopharma leader Gilead Sciences officially opened its new Beijing office. Terry Branstad, United States Ambassador to China, joined the celebration in Gilead’s new office and addressed the audience. The Ambassador acknowledged Gilead’s contributions to fighting devastating diseases, including finding the cure for HCV. Ambassador Branstad stated that the new Beijing office will strengthen healthcare collaboration between the US and China as the two countries share similar challenges given their aging populations.
Branstad went on to urge the company to continue to strive to help tens of millions of patients in China. Guests included Eric Hirsch, Vice Chairman of AmCham China, Ningning Hu, Deputy Director General of China Primary Health Care Foundation, Li Xiangming, General Manager of China Resources Pharmaceutical Commercial Group Xiangming Li, and a number of leading physicians specializing in hepatitis and infectious diseases. Eric Hirsch extended his congratulatory remarks on AmCham China’s behalf. Rogers Luo, Gilead Global VP and China GM, hosted the event.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Gilead formally established its commercial operations in China in 2016. Within two years, it has expanded into a company with over 250 employees, had three important products in HCV & HIV approved in China, one of which has been included in several local reimbursement lists, and one has been included into the national Essential Drugs Lists. It is aspiring to support the Chinese government to realize “a nation free of hepatitis diseases”.
